Trial Profile
Phase 3B, Randomized Trail of Revlimid (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms ARUMM
- Sponsors Celgene Corporation
- 13 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 Feb 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record. (Global end date:2020-10-12)
- 27 Jan 2021 This trial has been completed in Greece, according to European Clinical Trials Database record. (Global end date:2020-10-12)